Hizal, M. Et Al. 2023. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). Journal of Cancer Research and Clinical Oncology , vol.149, no.8 , 4141-4148.

Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... Güven, D. C.(2023). The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). Journal of Cancer Research and Clinical Oncology , vol.149, no.8, 4141-4148.

Hizal, Mutlu Et Al. "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)," Journal of Cancer Research and Clinical Oncology , vol.149, no.8, 4141-4148, 2023

Hizal, Mutlu Et Al. "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)." Journal of Cancer Research and Clinical Oncology , vol.149, no.8, pp.4141-4148, 2023

Hizal, M. Et Al. (2023) . "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)." Journal of Cancer Research and Clinical Oncology , vol.149, no.8, pp.4141-4148.

@article{article, author={Mutlu Hizal Et Al. }, title={The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)}, journal={Journal of Cancer Research and Clinical Oncology}, year=2023, pages={4141-4148} }